0
0
Home » Pharmaceuticals

Dengue Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Global Markets Direct’s, ‘Dengue Fever – Drugs In Development, 2021’, provides an overview of the Dengue Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dengue Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The report provides a snapshot of the global therapeutic landscape of Dengue Fever

– The report reviews pipeline therapeutics for Dengue Fever Hypogonadism by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Dengue Fever Hypogonadism therapeutics and enlists all their major and minor projects

– The report assesses Dengue Fever Hypogonadism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Dengue Fever

Reasons to Buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand important and diverse types of therapeutics under development for Dengue Fever

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Dengue Fever pipeline depth and focus of Indication therapeutics

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Key Players

60 Degrees Pharmaceuticals LLC

Abhelix LLC

Abivax SA

AbViro LLC

Atea Pharmaceuticals Inc

Avida Biotech SL

Biological Mimetics Inc

BioNet-Asia Co Ltd

Biotron Ltd

Cadila Healthcare Ltd

Cidara Therapeutics Inc

Codagenix Inc

CycloLab Cyclodextrin Research and Development Laboratory Ltd

Emergex Vaccines Holding Ltd

Ennaid Therapeutics LLC

Etna Biotech Srl

Excivion Ltd

Exopharm Ltd

Globavir Biosciences Inc

Greffex Inc

Hercules Pharmaceuticals BV

HSRx Group

ImmuneMed Inc

Immunotope Inc

Imutex Ltd

Indian Immunologicals Ltd

Inovio Pharmaceuticals Inc

Integral Molecular Inc

Island Pharmaceuticals

Johnson & Johnson

KinoPharma Inc

KM Biologics Co Ltd

Macrophage Therapeutics Inc

Medigen Inc

Moleculin Biotech Inc

Najit Technologies Inc

Novartis AG

Orgenesis Inc

Panacea Biotec Ltd

Plex Pharmaceuticals Inc

ProtInhi BV

Riboscience LLC

Seagull BioSolutions Pvt Ltd

Serum Institute of India Pvt Ltd

Shionogi & Co Ltd

Sun Pharma Advanced Research Company Ltd

Takeda Pharmaceutical Co Ltd

TechnoVax Inc

Theravectys SA

Vir Biotechnology Inc

Virocovax

Visterra Inc

VLP Therapeutics LLC

Xenothera SAS

Zucero Therapeutics Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Dengue Fever – Overview

Dengue Fever – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Dengue Fever – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Dengue Fever – Companies Involved in Therapeutics Development

(dengue + zika) (pentavalent) vaccine – Drug Profile

Dengue Fever – Dormant Projects

Dengue Fever – Discontinued Products

Dengue Fever – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Dengue Fever, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Dengue Fever – Dormant Projects, 2021

Dengue Fever – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Dengue Fever, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2960

Join our mailing list

Saved reports